Evidence map›Paper›PMID 36050391›Full record

ArticleNPJ precision oncology2022

Spatially variant immune infiltration scoring in human cancer tissues.

Mayar Allam, Thomas Hu, Jeongjin Lee, Jeffrey Aldrich, Sunil S Badve, Yesim Gökmen-Polar, Manali Bhave, Suresh S Ramalingam, Frank Schneider, Ahmet F Coskun

Open access · goldAbstract read
In one paragraph

Article in NPJ precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. iScience · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mayar Allam *Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-1550-2316
Thomas Hu *Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7801-7070
Jeongjin LeeWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-0376-1441
Jeffrey AldrichDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Sunil S BadveWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Yesim Gökmen-PolarWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Manali BhaveDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Suresh S RamalingamDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Frank SchneiderWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Ahmet F CoskunWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA. ahmet.coskun@bme.gatech.edu.ORCID http://orcid.org/0000-0002-5797-1524
Emory University · USGeorgia Institute of Technology · US

Funding

Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2019 to 2024
$10.1M
Burroughs Wellcome Fund (BWF) CASINCI NIH HHS P50 CA217691U.S. Department of Health & Human Services | National Institutes of Health (NIH) P50CA217691-CEP
6 · The paper itself

Abstract

The Immunoscore is a method to quantify the immune cell infiltration within cancers to predict the disease prognosis. Previous immune profiling approaches relied on limited immune markers to establish patients' tumor immunity. However, immune cells exhibit a higher-level complexity that is typically not obtained by the conventional immunohistochemistry methods. Herein, we present a spatially variant immune infiltration score, termed as SpatialVizScore, to quantify immune cells infiltration within lung tumor samples using multiplex protein imaging data. Imaging mass cytometry (IMC) was used to target 26 markers in tumors to identify stromal, immune, and cancer cell states within 26 human tissues from lung cancer patients. Unsupervised clustering methods dissected the spatial infiltration of cells in tissue using the high-dimensional analysis of 16 immune markers and other cancer and stroma enriched labels to profile alterations in the tumors' immune infiltration patterns. Spatially resolved maps of distinct tumors determined the spatial proximity and neighborhoods of immune-cancer cell pairs. These SpatialVizScore maps provided a ranking of patients' tumors consisting of immune inflamed, immune suppressed, and immune cold states, demonstrating the tumor's immune continuum assigned to three distinct infiltration score ranges. Several inflammatory and suppressive immune markers were used to establish the cell-based scoring schemes at the single-cell and pixel-level, depicting the cellular spectra in diverse lung tissues. Thus, SpatialVizScore is an emerging quantitative method to deeply study tumor immunology in cancer tissues.

Identifiers

PMID36050391
PMCPMC9437065
OpenAlexW4294031571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.